KeyZell develops LZ-167, a targeted therapeutic agent designed to attack tumor cells with high specificity while preserving healthy tissue in cancer treatment. The company integrates this pharmaceutical development with proprietary artificial intelligence platforms for precision oncology applications. This approach aims to provide effective, accessible, and scalable treatment options for cancer patients globally.
Funding
$510K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer treatment selection is a complex process, often leading to inefficiencies and increased costs due to the vast amount of genomic and molecular data that must be analyzed. Current methods can be slow and may not always result in the most effective treatment plan for individual patients.
Solution
KeyZell is developing an AI-driven Oncology Precision System (OPS) designed to enhance treatment selection and reduce costs in cancer care. The system integrates genomic, molecular, and clinical data to provide personalized treatment recommendations. By leveraging machine learning algorithms, KeyZell's OPS analyzes data to predict the most effective treatment options, monitor patient progress, and identify relevant biomarkers. The platform aims to improve the precision of cancer diagnostics and treatment, ultimately leading to better patient outcomes and a higher quality of life. Keyzell's Oncology Diagnostic System (ODS) improves the precision of all phases of the medical oncology process.
Target Audience
KeyZell's primary target audience includes oncologists, medical professionals, and healthcare providers seeking to improve the precision and efficiency of cancer treatment selection.
Features
- AI-driven analysis of genomic, molecular, and clinical data
- Prediction of personalized cancer treatments based on individual patient profiles
- Integration of Oncology Precision System (OPS) and Oncology Diagnostic System (ODS)
- Monitoring of patient progress during treatment
- Identification of relevant biomarkers for targeted therapies
- Trained with hundreds of thousands of clinical data points
- Analysis of up to 112 useful biomarkers